Stockscreener 앱 받기
15.74
0.32%
-0.05
전일 마감가:
$15.79
열려 있는:
$16.02
하루 거래량:
425.93K
Relative Volume:
0.69
시가총액:
$1.10B
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-5.4464
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
-3.49%
1개월 성능:
-23.03%
6개월 성능:
-9.54%
1년 성능:
-34.66%
1일 변동 폭
$15.57
$16.14
1주일 범위
$15.53
$16.68
52주 변동 폭
$15.31
$27.24
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
XNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
15.74 | 1.10B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Xencor (XNCR) Projected to Post Earnings on Tuesday - MarketBeat
When (XNCR) Moves Investors should Listen - Stock Traders Daily
Louisiana State Employees Retirement System Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor reports financial restatements, cites errors - MSN
Xencor, Inc. Enters License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat Covid-19 with Vir Biotechnology - Marketscreener.com
Xencor (NASDAQ:XNCR) Receives Response from RSM US LLP on Form 8-K FilingSan Francisco-based Xencor, Inc. recently received a response from RSM US LLP regarding the statements included in Item 4.02(b) of its Form 8-K filed on February 13, 2025 - Defense World
Xencor reports financial restatements, cites errors By Investing.com - Investing.com UK
Essex LLC Cuts Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Wells Fargo gives an Overweight recommendation for Xencor Inc (XNCR) - Knox Daily
Xencor Inc (XNCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet - MSN
Objective long/short (XNCR) Report - Stock Traders Daily
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
BlackRock, Inc. Increases Stake in Xencor Inc. - GuruFocus.com
Ratios Reveal: Breaking Down Xencor Inc (XNCR)’s Financial Health - The Dwinnex
Xencor's SWOT analysis: biotech stock faces mixed outlook amid pipeline progress - MSN
Xencor Inc [XNCR] Stock sold by Insider Montgomery Alan Bruce for $0.36 million - Knox Daily
Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27% - Simply Wall St
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week - Yahoo Finance
Xencor, Inc. (NASDAQ:XNCR) Short Interest Up 21.4% in January - Defense World
Xencor: Substantial Promise, Slow Progress (NASDAQ:XNCR) - Seeking Alpha
(XNCR) Investment Analysis - Stock Traders Daily
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy - Simply Wall St
Xencor's SWOT analysis: biotech stock navigates pipeline progress amid market challenges - MSN
Xencor (NASDAQ:XNCR) Trading Down 3.9%Should You Sell? - MarketBeat
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround - MSN
JPMorgan Chase & Co. Acquires 3,635 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR) - Yahoo Finance
Xencor (NASDAQ:XNCR) Stock Price Down 3.8%What's Next? - MarketBeat
Xencor Becomes Oversold (XNCR) - Nasdaq
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know - MSN
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks - Yahoo Finance
Xencor Highlights Progress in Drug Development Pipeline - TipRanks
Xencor (NASDAQ:XNCR) Trading Down 9.3%Here's Why - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
How To Trade (XNCR) - Stock Traders Daily
Are Broader Antibody Patents Possible in US Through Means-Plus-Function Claiming? - JD Supra
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Principal Financial Group Inc. - Defense World
Is Xencor (NASDAQ:XNCR) Using Too Much Debt? - Simply Wall St
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xencor Inc 주식 (XNCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dahiyat Bassil I | PRESIDENT & CEO |
Feb 03 '25 |
Option Exercise |
15.69 |
8,808 |
138,198 |
375,390 |
| Montgomery Alan Bruce | Director |
Dec 02 '24 |
Option Exercise |
17.10 |
13,301 |
227,458 |
22,441 |
| Montgomery Alan Bruce | Director |
Dec 04 '24 |
Option Exercise |
16.76 |
1,421 |
23,812 |
10,561 |
| Montgomery Alan Bruce | Director |
Dec 02 '24 |
Sale |
27.03 |
13,301 |
359,525 |
9,140 |
| Montgomery Alan Bruce | Director |
Dec 04 '24 |
Sale |
27.03 |
1,421 |
38,406 |
9,140 |
0.27%
3.05%
자본화:
|
볼륨(24시간):